| Dr Shannon Wayne Altazan, DO | |
|
3110 Maccorkle Ave Se, Charleston, WV 25304-1210 | |
| (304) 388-7170 | |
| Not Available |
| Full Name | Dr Shannon Wayne Altazan |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 3110 Maccorkle Ave Se, Charleston, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477057883 | NPI | - | NPPES |
| 0485813 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 3742 (West Virginia) | Secondary |
| 207P00000X | Emergency Medicine | 34.015793 (Ohio) | Primary |
| Entity Name | Epmg Of Ohio Inc P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841232196 PECOS PAC ID: 1052223799 Enrollment ID: O20031103000158 |
News Archive
The first successful report of using cell-depleted lung as a natural growth matrix for generating new rat lung from embryonic stem cells is presented in a breakthrough article in Tissue Engineering, Part A, a peer-reviewed journal published by Mary Ann Liebert, Inc..
AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Here we go again. It's been a month since Democratic presidential hopefuls last took to the debate stage, but Tuesday night in Detroit 10 candidates again faced off for the first of this two-night event.
› Verified 1 days ago
| Entity Name | Steel Valley Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831145275 PECOS PAC ID: 3577511195 Enrollment ID: O20050110000903 |
News Archive
The first successful report of using cell-depleted lung as a natural growth matrix for generating new rat lung from embryonic stem cells is presented in a breakthrough article in Tissue Engineering, Part A, a peer-reviewed journal published by Mary Ann Liebert, Inc..
AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Here we go again. It's been a month since Democratic presidential hopefuls last took to the debate stage, but Tuesday night in Detroit 10 candidates again faced off for the first of this two-night event.
› Verified 1 days ago
| Entity Name | Trinity Hospital Twin City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992096192 PECOS PAC ID: 6204004534 Enrollment ID: O20111206000207 |
News Archive
The first successful report of using cell-depleted lung as a natural growth matrix for generating new rat lung from embryonic stem cells is presented in a breakthrough article in Tissue Engineering, Part A, a peer-reviewed journal published by Mary Ann Liebert, Inc..
AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Here we go again. It's been a month since Democratic presidential hopefuls last took to the debate stage, but Tuesday night in Detroit 10 candidates again faced off for the first of this two-night event.
› Verified 1 days ago
| Entity Name | Columbiana Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336618628 PECOS PAC ID: 9830437508 Enrollment ID: O20190205003349 |
News Archive
The first successful report of using cell-depleted lung as a natural growth matrix for generating new rat lung from embryonic stem cells is presented in a breakthrough article in Tissue Engineering, Part A, a peer-reviewed journal published by Mary Ann Liebert, Inc..
AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Here we go again. It's been a month since Democratic presidential hopefuls last took to the debate stage, but Tuesday night in Detroit 10 candidates again faced off for the first of this two-night event.
› Verified 1 days ago
| Entity Name | East Ohio Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508480930 PECOS PAC ID: 6305260753 Enrollment ID: O20200720000706 |
News Archive
The first successful report of using cell-depleted lung as a natural growth matrix for generating new rat lung from embryonic stem cells is presented in a breakthrough article in Tissue Engineering, Part A, a peer-reviewed journal published by Mary Ann Liebert, Inc..
AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Here we go again. It's been a month since Democratic presidential hopefuls last took to the debate stage, but Tuesday night in Detroit 10 candidates again faced off for the first of this two-night event.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shannon Wayne Altazan, DO 3110 Maccorkle Ave Se, Charleston, WV 25304-1210 Ph: () - | Dr Shannon Wayne Altazan, DO 3110 Maccorkle Ave Se, Charleston, WV 25304-1210 Ph: (304) 388-7170 |
News Archive
The first successful report of using cell-depleted lung as a natural growth matrix for generating new rat lung from embryonic stem cells is presented in a breakthrough article in Tissue Engineering, Part A, a peer-reviewed journal published by Mary Ann Liebert, Inc..
AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Here we go again. It's been a month since Democratic presidential hopefuls last took to the debate stage, but Tuesday night in Detroit 10 candidates again faced off for the first of this two-night event.
› Verified 1 days ago
Barry Michael Mitchell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 419 Brooks St, Charleston, WV 25301 Phone: 304-395-0401 | |
Adam Thomas Crawford, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3110 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-7170 Fax: 304-388-4621 | |
Dr. Hunter Nielsen, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Morris St, Charleston, WV 25301 Phone: 304-388-5432 Fax: 304-388-3360 | |
Lauren B Wright, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3200 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-4172 Fax: 304-388-4155 | |
Bradley Nine, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3200 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-5432 | |
Calvin Huan Yang, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-4172 Fax: 304-388-4155 | |
Roger Taylor, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Morris St, Charleston, WV 25301 Phone: 304-647-6006 |